Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from preventive infectious disease vaccines.

D K F Chandler1, K Midthun, K L Goldenthal

  • 1Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Research and Review, US Food and Drug Administration, Rockville, MD, USA. chandler@cber.fda.gov

Developments in Biologicals
|December 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

Vaccine·2011
Same author

Human papillomavirus and HPV vaccines: a review.

Bulletin of the World Health Organization·2007
Same author

Prelicensure evaluation of combination vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Developing new smallpox vaccines.

Emerging infectious diseases·2001
Same author

Intent-to-treat analysis and preventive vaccine efficacy.

Vaccine·2000
Same author

Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.

AIDS research and human retroviruses·2000
Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013
Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013
Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013
Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013
Same journal

Schmallenberg virus.

Developments in biologicals·2013
Same journal

Classical swine fever.

Developments in biologicals·2013
See all related articles

Regulatory requirements for preventive vaccines ensure safety, purity, and potency. Key considerations include manufacturing, quality control, preclinical and clinical development, and lot release testing for infectious disease indications.

Area of Science:

  • Vaccinology
  • Regulatory Science
  • Biologics Manufacturing

Background:

  • Preventive vaccines for infectious diseases are regulated by the FDA's Office of Vaccines Research and Review.
  • FDA-regulated biological products, including vaccines, must meet stringent standards for safety, purity, potency, and consistent manufacturing.
  • Adherence to current Good Manufacturing Practices is mandatory for vaccine production.

Purpose of the Study:

  • To outline the regulatory landscape and key considerations for the development and approval of preventive vaccines.
  • To detail the essential components of vaccine regulation, from production to clinical trials.
  • To highlight critical data requirements for regulatory submissions, including preclinical and clinical data.

Main Methods:

Related Experiment Videos

  • Review of regulatory principles for vaccine production and quality control.
  • Examination of requirements for preclinical data and clinical development, including Phase 3 studies.
  • Discussion of lot release testing, assay validation, and consistency studies.

    • Main Results:

    • Vaccine development necessitates rigorous adherence to Good Manufacturing Practices.
    • Phase 3 studies require defined disease case definitions and adequate sample sizes for efficacy and safety.
    • Validation of immunological assays and clinical lot consistency are crucial.

    Conclusions:

    • Successful vaccine regulation hinges on robust manufacturing, comprehensive testing, and thorough clinical evaluation.
    • Bridging studies may be necessary to support manufacturing changes or population extrapolations.
    • Ensuring vaccine safety, purity, and potency is paramount throughout the development lifecycle.